Colonial Trust Advisors Raises Position in Kenvue Inc. (NYSE:KVUE)

Colonial Trust Advisors boosted its holdings in Kenvue Inc. (NYSE:KVUE) by 1.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 156,634 shares of the company’s stock after buying an additional 2,510 shares during the period. Colonial Trust Advisors’ holdings in Kenvue were worth $3,344,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in Kenvue by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company’s stock valued at $4,665,908,000 after buying an additional 1,636,741 shares during the period. Massachusetts Financial Services Co. MA raised its stake in Kenvue by 12.3% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company’s stock worth $2,085,070,000 after buying an additional 10,682,003 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Kenvue by 3.1% during the fourth quarter. Geode Capital Management LLC now owns 46,068,931 shares of the company’s stock valued at $980,989,000 after purchasing an additional 1,391,854 shares in the last quarter. Franklin Resources Inc. increased its stake in shares of Kenvue by 61.5% during the fourth quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company’s stock valued at $912,059,000 after purchasing an additional 16,269,721 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Kenvue by 2.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 24,972,777 shares of the company’s stock valued at $533,169,000 after buying an additional 561,570 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Stock Performance

NYSE:KVUE opened at $21.79 on Thursday. The firm has a market cap of $41.65 billion, a price-to-earnings ratio of 41.11, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The firm’s fifty day moving average price is $22.61 and its 200 day moving average price is $22.42. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, sell-side analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were issued a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.76%. Kenvue’s payout ratio is 154.72%.

Analyst Ratings Changes

KVUE has been the topic of several research reports. Royal Bank of Canada restated a “sector perform” rating and issued a $24.00 target price on shares of Kenvue in a report on Monday, February 3rd. Evercore ISI started coverage on shares of Kenvue in a research report on Monday, March 24th. They set an “in-line” rating and a $25.00 price objective on the stock. UBS Group reduced their price target on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a report on Friday, February 7th. Barclays lifted their price objective on shares of Kenvue from $21.00 to $23.00 and gave the stock an “equal weight” rating in a research note on Thursday, March 27th. Finally, Canaccord Genuity Group lifted their price target on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $24.00.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.